RheumaGen is a gene-editing technology company focused on developing therapeutics that target the HLA gene to prevent the immune system from attacking healthy cells in rheumatoid arthritis. By addressing the genetic triggers of autoimmune diseases, RheumaGen aims to provide a curative approach rather than merely managing symptoms.
Funding
$15M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Rheumatoid arthritis and other autoimmune diseases occur when the immune system mistakenly attacks healthy cells, leading to chronic inflammation and tissue damage. Current treatments primarily focus on managing symptoms or suppressing the entire immune system, rather than addressing the underlying genetic cause of the autoimmune response. This often results in incomplete relief and potential side effects.
Solution
RheumaGen is developing gene-editing therapeutics that target the Human Leukocyte Antigen (HLA) gene, which plays a critical role in the genetic origin of autoimmune diseases. By precisely editing the HLA gene, RheumaGen aims to prevent the immune system from attacking healthy cells, effectively addressing the root cause of the autoimmune response. This approach offers the potential for a curative therapy rather than merely managing the downstream symptoms of rheumatoid arthritis and other autoimmune conditions. RheumaGen's technology seeks to selectively "turn off" the genetic trigger that causes the immune system to misidentify and attack the body's own tissues.
Target Audience
RheumaGen's primary target audience includes individuals suffering from rheumatoid arthritis and other autoimmune diseases with a genetic predisposition linked to HLA genes.
Features
- Gene-editing technology specifically targeting the HLA gene
- Therapeutic approach designed to prevent the immune system from attacking healthy cells in autoimmune diseases
- Potential for curative treatment by addressing the genetic origin of autoimmunity
- Selective modulation of the immune response, minimizing broad immunosuppression